ArticleNPJ precision oncology2025
Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo axis.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Fer Tyrosine Kinase Mediates EGFR Activation in Sperm Capacitation.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
FER, an intracellular tyrosine kinase, is ubiquitously expressed in malignancies. However, the regulatory mechanisms of FER in diffuse large B-cell lymphoma (DLBCL) remain elusive. Here, we found that FER was upregulated in DLBCL, leading to unfavorable outcomes and increased tumorigenesis, as well as resistance to chemotherapy. While exposing cells to the FER inhibitor E260, cell proliferation and tumor growth were repressed. Moreover, greater tumor suppression resulted from combining exosome-E260 with chemotherapeutics compared with the suppression achieved by monotherapy. Mechanistically, E260 restored the activity of Hippo signaling by inhibiting AJUBA, resulting in YAP cytoplasmic sequestration. Furthermore, circulating exosomal FER may act as an indicator for the diagnosis and progression of DLBCL. In summary, FER could serve as a prognostic indicator and therapeutic target in DLBCL. Additionally, the application of exosomes in diagnosis or treatment may open up novel avenues for cancer therapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.